Names
Omidubicel-onlv Omisirge®Indications and usage
Oomidubicel-onlv is indicated for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
Side effects needing medical attention
The most common adverse reactions are infections, GvHD, and infusion reaction.